🇪🇺 ADAKVEO in European Union

EMA authorised ADAKVEO on 28 October 2020

Marketing authorisation

EMA — authorised 28 October 2020

  • Application: EMEA/H/C/004874
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Adakveo
  • Indication: Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.
  • Pathway: conditional
  • Status: withdrawn

Read official source →

ADAKVEO in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is ADAKVEO approved in European Union?

Yes. EMA authorised it on 28 October 2020.

Who is the marketing authorisation holder for ADAKVEO in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.